Smartkarma AI Synthetic Expert Call Transcripts, Smartkarma

αSK SmartScripts

Smartkarma AI Synthetic Expert Call Transcripts

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.

<ul><li>Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the clinical superiority of bispecific antibody mechanisms over monotherapies, but shifting the global standard of care requires multi-regional Phase III validation across broader Western demographics.</li><li>Akeso’s domestic growth remains robust with H1 2026 product sales reaching RMB 1,803.2 million, though NRDL price reductions have normalized gross margins to 79%; international enterprise value hinges on out-licensed royalty monetization and regulatory success, including Summit’s November 14, 2026 PDUFA decision.</li><li>The HK$1.94 billion ($249 million) equity placement on October 13, 2026 at HK$97.76 per share reflects a proactive capital strategy to fully fund global registrational trials like COMPASSION-37 independently rather than relying solely on Western partners.</li></ul><div style="color: #475569; background: #eee; border-radius: 16px; padding: 14px; margin: 14px 0; font-size: 12px; line-height: 16px;">Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.</div>

Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the clinical superiority of bispecific antibody mechanisms over monotherapies, but shifting the global standard of care requires multi-regional Phase III validation across broader Western demographics.Akeso’s domestic growth remains robust with H1 2026 product sales reaching RMB 1,803.2 million, though NRDL price reductions have normalized gross margins to 79%; international enterprise value hinges on out-licensed royalty monetization and regulatory success, including Summit’s November 14, 2026 PDUFA decision.The HK$1.94 billion ($249 million) equity placement on October 13, 2026 at HK$97.76 per share reflects a proactive capital strategy to fully fund global registrational trials like COMPASSION-37 independently rather than relying solely on Western partners.Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.

Akeso (9926 HK): Synthetic Expert Call Transcript (14 Oct 2026)

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

Beijing Wantai Biological Phar / Index Rebalance

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. manufactures medical products. The Company produces enzyme linked immunodiagnostic reagents, colloidal gold rapid diagnostic reagents, vaccines, biochemical reagents, and other products. Beijing Wantai Biological Pharmacy Enterprise also produces diagnostic equipment.

Beijing Wantai Biological Phar (603392 CH)

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.</li>
<li>We expect five ADDs/DELs for the CSI Medical Service index during the upcoming index rebal  event based on the latest available data.</li>
<li>Nearly 95% of the reference period is now complete. We currently estimate one-way flow to be US$301mn.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
We expect five ADDs/DELs for the CSI Medical Service index during the upcoming index rebal  event based on the latest available data.
Nearly 95% of the reference period is now complete. We currently estimate one-way flow to be US$301mn.


Quiddity Leaderboard CSI Medical Dec26: Expectations Have Changed; US$301mn One-Way

DapuStor Corporation designs and manufactures computer storage products. The Company produces solid-state drives (SSD), data storage processor chips, and edge computing-related products. DapuStor provides products for servers, telecom operators, and data centers.

<ul>
<li>ChiNext and ChiNext 50, respectively, represent the top 100 and top 50 A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.</li>
<li>We expect 7 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.</li>
<li>With approximately 91% of the review period complete, the rankings have largely stabilized.</li>
</ul>


ChiNext and ChiNext 50, respectively, represent the top 100 and top 50 A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.
We expect 7 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.
With approximately 91% of the review period complete, the rankings have largely stabilized.


Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Expected ADDs Sharply Down Vs Expected DELs

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the 3Q2026 Shanghai/Shenzhen northbound Connect flows with our data engine as the exchange changed the rule to only disclose north bound position once a quarter.</li>
<li>We estimate that the outflows in 3Q2026 were US$12,576 million and holdings were US$386 billion.</li>
<li>We highlight flows for CATL, EOPTOLINK TECHNOLOGY, NAURA TECHNOLOGY, WEICHAI POWER, ZIJIN MINING, ZHONGJI INNOLIGHT, CMB, WUXI APPTEC, PING AN INSURANCE, MIDEA.</li>
</ul>


We analyze the 3Q2026 Shanghai/Shenzhen northbound Connect flows with our data engine as the exchange changed the rule to only disclose north bound position once a quarter.
We estimate that the outflows in 3Q2026 were US$12,576 million and holdings were US$386 billion.
We highlight flows for CATL, EOPTOLINK TECHNOLOGY, NAURA TECHNOLOGY, WEICHAI POWER, ZIJIN MINING, ZHONGJI INNOLIGHT, CMB, WUXI APPTEC, PING AN INSURANCE, MIDEA.


Northbound Flows (3Q2026): CATL, EOPTOLINK TECHNOLOGY, NAURA TECHNOLOGY, WEICHAI POWER, ZIJIN MINING

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Shenzhen Han's CNC Technology / Equity Bottom-Up

Shenzhen Han's CNC Technology is a national high-tech enterprise specializing in the R&D, manufacturing, and sales of special equipment for printed circuit boards (PCBs). The company offers one-stop solutions for PCB manufacturers, including equipment for drilling, exposure, routing, electrical performance testing, and stiffening. It was founded on April 22, 2002, and is headquartered in Shenzhen, Guangdong Province, China.

<ul>
 <li>
<a href="https://smartkarma.com/entities/shenzhen-han-s-cnc-technology-co-ltd-class-h">Shenzhen Han's CNC Technology</a> (3200 HK / 301200 SZ) is China's premier PCB equipment manufacturer, positioned as the primary equipment beneficiary of the secular supercycle in artificial intelligence (AI) data centers, high-layer High-Density Interconnect (HDI) boards, and advanced IC packaging substrates.</li>
 <li>The company's financial execution has inflected sharply, with FY25 revenue surging 72.4% YoY to RMB 6,237.62 million and net profit jumping 173.8% YoY to RMB 893.94 million, followed by an extraordinary 1H26 performance where revenue reached RMB 5,693.58 million (+122.3% YoY) and net profit exceeded full-year FY25 at RMB 1,094.07 million with EBITDA margins reaching 23.58% in 2Q26.</li>
 <li>Following its landmark dual-listing on the Hong Kong Stock Exchange in February 2026 and the subsequent digestion of the US$311 million cornerstone investor lockup expiry in August 2026, the stock at HK$77.25 offers institutional investors an attractive entry valuation relative to its triple-digit operational growth and global equipment peer multiples.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Shenzhen Han's CNC Technology (3200 HK / 301200 SZ) is China's premier PCB equipment manufacturer, positioned as the primary equipment beneficiary of the secular supercycle in artificial intelligence (AI) data centers, high-layer High-Density Interconnect (HDI) boards, and advanced IC packaging substrates.
  The company's financial execution has inflected sharply, with FY25 revenue surging 72.4% YoY to RMB 6,237.62 million and net profit jumping 173.8% YoY to RMB 893.94 million, followed by an extraordinary 1H26 performance where revenue reached RMB 5,693.58 million (+122.3% YoY) and net profit exceeded full-year FY25 at RMB 1,094.07 million with EBITDA margins reaching 23.58% in 2Q26.
  Following its landmark dual-listing on the Hong Kong Stock Exchange in February 2026 and the subsequent digestion of the US$311 million cornerstone investor lockup expiry in August 2026, the stock at HK$77.25 offers institutional investors an attractive entry valuation relative to its triple-digit operational growth and global equipment peer multiples.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Shenzhen Han's CNC Technology (3200 HK) - Oct 2026